{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:56:17Z","timestamp":1783137377228,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40262-021-01081-3","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T06:02:45Z","timestamp":1636783365000},"page":"423-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition"],"prefix":"10.1007","volume":"61","author":[{"given":"Amina","family":"Bensalem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Desvignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lepr\u00eatre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4020-4545","authenticated-orcid":false,"given":"David","family":"Ternant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"issue":"7","key":"1081_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Ternant D. Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2020;59(7):857\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1081_CR2","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood.V110.11.2371.2371","volume":"110","author":"ML Jing Li","year":"2007","unstructured":"Jing Li ML, Charoin J-E, Frey N, Kheoh T, Ren S, Woo M, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin\u2019s lymphoma (NHL) patients. Blood. 2007;110(11):2371.","journal-title":"Blood"},{"issue":"8","key":"1081_CR3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bcp.13271","volume":"83","author":"S Rozman","year":"2017","unstructured":"Rozman S, Grabnar I, Novakovic S, Mrhar A, Jezersek NB. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol. 2017;83(8):1782\u201390.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1081_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40262-016-0470-8","volume":"56","author":"M Tout","year":"2017","unstructured":"Tout M, Gagez AL, Lepretre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, et al. Influence of FCGR3A-158V\/F genotype and baseline CD20 antigen count on target-mediated elimination of rituximab in patients with chronic lymphocytic leukemia: a study of FILO Group. Clin Pharmacokinet. 2017;56(6):635\u201347.","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"1081_CR5","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129(19):2616\u201323.","journal-title":"Blood"},{"issue":"6","key":"1081_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","volume":"27","author":"MB Regazzi","year":"2005","unstructured":"Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27(6):785\u201392.","journal-title":"Ther Drug Monit"},{"issue":"14","key":"1081_CR7","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C Muller","year":"2012","unstructured":"Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119(14):3276\u201384.","journal-title":"Blood"},{"issue":"3","key":"1081_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","volume":"81","author":"M Candelaria","year":"2018","unstructured":"Candelaria M, Gonzalez D, Fernandez Gomez FJ, Paravisini A, Del Campo GA, Perez L, et al. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother Pharmacol. 2018;81(3):515\u201327.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1081_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1472-8206.2009.00714.x","volume":"23","author":"H Blasco","year":"2009","unstructured":"Blasco H, Chatelut E, de Bretagne IB, Congy-Jolivet N, Le Guellec C. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol. 2009;23(5):601\u20138.","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"1081_CR10","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52(12):1918\u201326.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1081_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bcp.12662","volume":"80","author":"S Assouline","year":"2015","unstructured":"Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, et al. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2015;80(5):1001\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1081_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.13270","volume":"83","author":"B Lioger","year":"2017","unstructured":"Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, et al. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol. 2017;83(8):1773\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1081_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45(7):792\u2013801.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1081_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/bcp.12098","volume":"76","author":"F Puisset","year":"2013","unstructured":"Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol. 2013;76(5):734\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1081_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-016-3083-x","volume":"78","author":"V Gota","year":"2016","unstructured":"Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, et al. Population pharmacokinetics of Reditux, a biosimilar rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016;78(2):353\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"1081_CR16","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/bcp.13991","volume":"85","author":"D Ternant","year":"2019","unstructured":"Ternant D, Monjanel H, Venel Y, Prunier-Aesch C, Arbion F, Colombat P, et al. Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: a pilot study. Br J Clin Pharmacol. 2019;85(9):2002\u201310.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1081_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11095-019-2605-8","volume":"36","author":"SM Lavezzi","year":"2019","unstructured":"Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, et al. Systemic exposure of rituximab increased by ibrutinib: pharmacokinetic results and modeling based on the HELIOS trial. Pharm Res. 2019;36(7):93.","journal-title":"Pharm Res"},{"issue":"12","key":"1081_CR18","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1111\/bcp.14102","volume":"85","author":"A Bensalem","year":"2019","unstructured":"Bensalem A, Mulleman D, Thibault G, Azzopardi N, Goupille P, Paintaud G, et al. CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. Br J Clin Pharmacol. 2019;85(12):2747\u201358.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1081_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40262-019-00826-5","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Mulleman D, Paintaud G, Azzopardi N, Gouilleux-Gruart V, Cornec D, et al. Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis: the RAVE trial revisited. Clin Pharmacokinet. 2020;59(4):519\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1081_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1060028018803587","volume":"53","author":"U Fogueri","year":"2019","unstructured":"Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS. Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother. 2019;53(4):357\u201363.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1081_CR21","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood.V110.11.2371.2371","volume":"110","author":"J Li","year":"2007","unstructured":"Li J, Levi M, Charoin J, Frey N, Kheoh T, Ren S, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin\u2019s lymphoma (NHL) patients. Blood. 2007;110(11):2371.","journal-title":"Blood"},{"key":"1081_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41401-020-0479-2","volume":"42","author":"S Liu","year":"2021","unstructured":"Liu S, Huang H, Chen RX, Wang Z, Guan YP, Peng C, et al. Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1\/2. Acta Pharmacol Sin. 2021;42:641\u20137.","journal-title":"Acta Pharmacol Sin."},{"issue":"2","key":"1081_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40262-018-0680-3","volume":"58","author":"D Ternant","year":"2019","unstructured":"Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G. Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans. Clin Pharmacokinet. 2019;58(2):169\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1081_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","volume":"8","author":"C Passot","year":"2016","unstructured":"Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs. 2016;8(7):1407\u201316.","journal-title":"MAbs"},{"key":"1081_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1876539401104010001","volume":"4","author":"UMP Specks","year":"2011","unstructured":"Specks UMP, Hoffman GS, Langford CA, Spiera R, Seo P, et al. Design of the rituximab in ANCA-associated vasculitis (RAVE) trial. Open Arthritis J. 2011;4:1\u201318.","journal-title":"Open Arthritis J."},{"issue":"3","key":"1081_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"1081_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jim.2007.06.011","volume":"325","author":"H Blasco","year":"2007","unstructured":"Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods. 2007;325(1\u20132):127\u201339.","journal-title":"J Immunol Methods"},{"issue":"12","key":"1081_CR28","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1021\/acs.analchem.6b00544","volume":"88","author":"JR Mills","year":"2016","unstructured":"Mills JR, Cornec D, Dasari S, Ladwig PM, Hummel AM, Cheu M, et al. Using mass spectrometry to quantify rituximab and perform individualized immunoglobulin phenotyping in ANCA-associated vasculitis. Anal Chem. 2016;88(12):6317\u201325.","journal-title":"Anal Chem"},{"issue":"4","key":"1081_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1365-2141.1995.tb08411.x","volume":"89","author":"TC Pearson","year":"1995","unstructured":"Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, et al. Interpretation of measured red cell mass and plasma volume in adults: expert panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995;89(4):748\u201356.","journal-title":"Br J Haematol"},{"issue":"11","key":"1081_CR30","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/art.38107","volume":"65","author":"J Melet","year":"2013","unstructured":"Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65(11):2783\u201390.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1081_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/rheumatology\/kex484","volume":"57","author":"D Cornec","year":"2018","unstructured":"Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR, et al. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford). 2018;57(4):639\u201350.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1081_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 20. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1081_CR33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41(6):1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1081_CR34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558\u201369.","journal-title":"AAPS J"},{"issue":"1","key":"1081_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10928-009-9143-7","volume":"37","author":"K Brendel","year":"2010","unstructured":"Brendel K, Comets E, Laffont C, Mentre F. Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn. 2010;37(1):49\u201365.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1081_CR36","unstructured":"RStudio Team. RStudio: integrated development for R. 2015. Boston: RStudio, Inc. http:\/\/www.rstudio.com\/. Accessed 13 Oct 2021."},{"key":"1081_CR37","unstructured":"Marc Lavielle. mlxR: simulation of longitudinal data. R package version 4.1.0. 2017. https:\/\/CRAN.R-project.org\/package=mlxR. Accessed 13 Oct 2021."},{"issue":"2","key":"1081_CR38","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S2352-3026(17)30235-1","volume":"5","author":"C Dartigeas","year":"2018","unstructured":"Dartigeas C, Van Den Neste E, Leger J, Maisonneuve H, Berthou C, Dilhuydy MS, et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018;5(2):e82-94.","journal-title":"Lancet Haematol."},{"issue":"6","key":"1081_CR39","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/cpt.1953","volume":"108","author":"HI Dai","year":"2020","unstructured":"Dai HI, Vugmeyster Y, Mangal N. Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther. 2020;108(6):1156\u201370.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1081_CR40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/bcp.13907","volume":"85","author":"F Le Louedec","year":"2019","unstructured":"Le Louedec F, Alix-Panabieres C, Lafont T, Allal BC, Garrel R, Digue L, et al. Cetuximab pharmacokinetic\/pharmacodynamics relationships in advanced head and neck carcinoma patients. Br J Clin Pharmacol. 2019;85(6):1357\u201366.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1081_CR41","doi-asserted-by":"publisher","first-page":"e2022","DOI":"10.1002\/onco.13564","volume":"25","author":"F Le Louedec","year":"2020","unstructured":"Le Louedec F, Chatelut E. Correlation between bevacizumab exposure and survival does not necessarily imply causality. Oncologist. 2020;25(12):e2022.","journal-title":"Oncologist"},{"issue":"2","key":"1081_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174\u201381.","journal-title":"Blood"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01081-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:04:43Z","timestamp":1646283883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01081-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01081-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"5 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was made using rituximab pharmacokinetic data belonging to the Lymphoma Study Association (France), French Innovative Leukemia Organization (FILO, France), Mayo Clinic (Rochester, MO, USA), and Tours University Hospital (Tours, France). The study in patients with diffuse large B-cell lymphoma and follicular lymphoma was funded by GELA and GOELAMS groups and F. Hoffman-La Roche Ltd (Basel, Switzerland). The study in chronic lymphocytic leukemia was funded by FILO Group and Roche SAS (Neuilly, France). The study comparing rituximab and cyclophosphamide in anti-neutrophil\u00a0<u>cytoplasmic<\/u>\u00a0autoantibody-associated vasculitis (RAVE) was supported by a grant from the National Institute of Allergy and Infectious Diseases to the Immune Tolerance Network (Grant N01-AI-15416; Protocol No. ITN021AI). Genentech, Inc. and Biogen IDEC, Inc. provided study medications and partial funding for this trial. Measurements of rituximab serum concentrations in patients with chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and rheumatoid arthritis were carried out by CePiBAc platform. CePiBAc is cofinanced by the European Union. Europe is committed to the r\u00e9gion Centre\u00a0Val-de-Loire with the European Regional Development Fund. CePiBac was partly supported by the French Higher Education and Research Ministry under the program \u2018Investissements d\u2019avenir\u2019 Grant Agreement: LabEx MAbImprove ANR-10-LABX-53-01. Genentech, Inc. measured rituximab concentrations by the enzyme-linked immunosorbent assay for the RAVE trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Guillaume Cartron received consultancy fees from Roche and Celgene, honoraria from Roche, Celgene, Jansen, Gilead, and Sanofi, and travel arrangements from Jansen, Gilead, and Sanofi. Emmanuel Gyan received research funding from Roche, is a coordinating investigator of a clinical trial supported by Roche, and received honoraria for scientific meetings organized by Roche. Olivier Casasnovas has acted as a consultant for and received honoraria from Roche, Gilead Sciences, Bristol Myers Squibb, Takeda, MSD, and AbbVie and has received research funding from Roche and Gilead. Gilles Paintaud reports grants received by his research team from Novartis, Roche Pharma, Genzyme, MSD, Chugai, and Pfizer, outside of the submitted work. Denis Mulleman reports grants from Abbvie and Nordic Pharma and consultancy fees for MSD, Novartis, UCB, and Pfizer. David Ternant reports lecture fees for Sanofi, Novartis, Amgen, and Boehringer Ingelheim. Amina Bensalem, Ulrich Specks, Divi Cornec, C\u00e9line Desvignes, Thierry Lamy, and St\u00e9phane Lepr\u00eatre have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies were approved by the local ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not Applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data and material are available upon request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code is available upon request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Amina Bensalem analyzed and interpreted the data and wrote the manuscript. Guillaume Cartron designed the clinical study in patients with diffuse large B-cell lymphoma and follicular lymphoma, and contributed to materials\/patients, was the principal investigator of the clinical study in patients with chronic lymphocytic leukemia, and reviewed the manuscript. Ulrich Specks was responsible for the design and coordination of the anti-neutrophil cytoplasmic antibody-associated vasculitis cohort, acquired the data, and reviewed the manuscript. Emmanuel Gyan contributed to materials\/patients in the clinical study in patients with diffuse large B-cell lymphoma and follicular lymphoma, and reviewed the manuscript. Gilles Paintaud designed the study in patients with chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma, participated in data interpretation, and reviewed the manuscript. Denis Mulleman was responsible for the design and coordination of the rheumatoid arthritis cohort, acquired the data, participated in data interpretation, and reviewed the manuscript. David Ternant designed the study in patients with diffuse large B-cell lymphoma, follicular lymphoma, and rheumatoid arthritis, supervised data analysis and interpretation, participated in the writing of the manuscript, and reviewed the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}